Everolimus for the Treatment of Tuberous Sclerosis Complex-Related Cardiac Rhabdomyomas in Pediatric Patients

J Pediatr. 2017 Nov:190:21-26.e7. doi: 10.1016/j.jpeds.2017.06.076. Epub 2017 Sep 6.

Author

Affiliation

¹ Division of Pediatric Cardiology, CHU Sainte-Justine, University of Montreal, Quebec, Canada. Electronic address: nagib.dahdah.hsj@ssss.gouv.qc.ca.

PMID: 28888564
DOI: 10.1016/j.jpeds.2017.06.076

No abstract available

Keywords: cardiac tumors; hamartomas; infants; mTOR inhibition.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Child, Preschool
Echocardiography / methods
Electrocardiography / methods
Everolimus / therapeutic use*
Female
Follow-Up Studies
Heart Neoplasms / diagnostic imaging*
Heart Neoplasms / drug therapy*
Heart Neoplasms / etiology
Humans
Infant
Infant, Newborn
Male
Rhabdomyoma / diagnostic imaging*
Rhabdomyoma / drug therapy*
Rhabdomyoma / etiology
Risk Assessment
Severity of Illness Index
Survival Rate
TOR Serine-Threonine Kinases / drug effects
TOR Serine-Threonine Kinases / genetics
Treatment Outcome
Tuberous Sclerosis / complications
Tuberous Sclerosis / diagnosis
Tuberous Sclerosis / drug therapy*

Substances

Everolimus
MTOR protein, human
TOR Serine-Threonine Kinases